ASX News
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| MTD | Ann: Removal from Official List | 04/01/16 | 0 | 1.3K | |||
|
|||||||
| MTD | Ann: Annual Report Jun 2015 | 16/09/15 | 0 | 1.3K | |||
|
|||||||
| MTD | Ann: Appendix 4D and Half Yearly Report Dec 2014 | 16/09/15 | 0 | 1.2K | |||
|
|||||||
| MTD | Ann: Preliminary Final Report | 31/08/15 | 0 | 2.0K | |||
|
|||||||
| MTD | Ann: Suspension from Official Quotation - Annual Listing Fees | 25/08/15 | 0 | 1.3K | |||
|
|||||||
| MTD | Ann: Change of Share Registry Name | 10/07/15 | 0 | 1.1K | |||
|
|||||||
| MTD | Ann: Extension To Due Diligence Period | 29/04/15 | 0 | 799 | |||
|
|||||||
| MTD | Ann: Extension To Due Diligence Period | 09/04/15 | 0 | 845 | |||
|
|||||||
See All Discussions
